Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human
Methods: We conducted a multicentric, retrospective study including adult pts with R/R B-NHL treated with BsAbs as last line of therapy and consolidated with HSCT. A control cohort of adult pts with R/R B-NHL treated with BsAbs who did not receive HSCT from a single institution was used. All pts received BsAb from April 2016 to July 2024 and had at least 3 lines of therapy before BsAb administration. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), non-relapse mortality (NRM) and relapse incidence/progression of disease (Rl/POD). The analysis started from the day of administration of the first dose of BsAb. A preplanned subanalysis for pts who reached PR/CR during BsAbs treatment was performed.
Results: Seventy-eight pts were enrolled. Forty-one (52.6%) pts received HSCT consolidation as per physician decision. The two groups (HSCT versus no consolidation) significantly differed in median age at BsAb administration (57 [range 22-71] vs 69 years [range 38-82], p=0.001), primary refractory disease (16 [39.0%] vs 8 [21.6%], p=0.001), prior administration of chimeric antigen T-cell receptor (20 [48.8%] vs 1 [2.7%], p<0.001), number of median lines at which BsAb was administered (4 [range 3-11] vs 3 [range 3-12], p=0.001) and type of administered BsAb (glofitamab 21 [51.2%] vs 17 [45.9%], epcoritamab 7 [17.1%] vs 20 [50.4%], mosunetuzumab 1 [2.4%] vs 0, ondronextamab 11 [26.8%] vs 0, BsAb antiCD22-CD3 1 [2.4%] vs 0, p<0.001). Median duration of BsAb treatment was 4.4 months (range 1.4-10.8) vs 3.5 months (range 0-48.4, p=0.620). Median number of BsAb administered doses was 12 (range 4-24) vs 11 (range 1-68)(p=0.394).
Of the 41 pts who proceeded to HSCT consolidation, 36 (87.8%) were in CR, 4 (9.8%) in PR and 1 (2.4%) in progressive disease (PD) before transplant. Median time from last BsAb dose to HSCT was 35 days (range 13-203). Type of donor was matched unrelated in 16 (39.0%), haploidentical in 16 (39.0%) and matched related in 9 (22.0%) pts. Thirty-eight (91.7%) pts received reduced intensity conditioning protocols, and 30 (73.2%) received post-transplant cyclophosphamide as graft-versus-host-disease prophylaxis.
Of the 37 pts who did not receive HSCT, overall response rate was 54% (n = 20) (CR rate 48.6% [n = 18]). Eight (21.6%) pts received a fixed number of doses of BsAb as per protocol. Early discontinuation of BsAb occurred in 25/29 pts (86.2%): 15 (40.5%) due to RI/POD, 8 (21.6%) due to toxicity and 2 (5.4%) due to other causes. Four pts (10.8%) had ongoing treatment at analysis. All grade cytokine release syndrome occurred in 18 pts (48.6%) with all being grade 1 or 2. All grade immune effector cell-associated neurotoxicity syndrome occurred in 2 pts (< grade 3). The median time to best response was 41 days (range 27-166). Median duration of best response was 23.1 months (range 0.9-77).
Median follow-up among survivors from the whole series was 20.6 months (22.3 months[range 4.6-86.4] for the HSCT cohort vs 16.6 months [range 0.7-76.8] for the not consolidated group). At 1-year, no differences were observed in univariate analysis in terms of PFS (61.8% vs 53.8%, p=0.077), OS (85.2% vs 59%, p=0.266) and NRM (15.9% vs 2.8%, p=0.122) among HSCT and no-consolidation cohorts. A lower RI/POD was observed in the HSCT group (8.5% vs 43.3%, p<0.001). In the subanalysis including only pts achieving PR/CR before HSCT (n=40) or during BsAb treatment without consolidation (n=20), no differences in terms of PFS (60.7 vs 84.7%, p=0.379), OS (84.8% vs 90%, p=0.437) and RI/POD (8.7% vs 15.3%, p=0.228) were found. However, a higher NRM was observed after HSCT(13.4% vs 0%, p=0.026).
Conclusions: HSCT consolidation does not seem to be associated with improved survival outcomes, especially for pts reaching a PR or CR during BsAb treatment. These results should be confirmed in a larger study population with a prolonged follow-up.
Disclosures: Qualls: Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees. Crombie: Genentech/Roche: Research Funding; ADCT: Consultancy; Genmab/Abbvie: Consultancy; Bayer: Research Funding; Genentech: Consultancy; Regeneron: Consultancy; Seagen: Consultancy; Abbvie: Research Funding; Merck: Research Funding. Serna: AbbVie: Honoraria; Incyte: Honoraria; Roche: Honoraria; Astrazeneca: Honoraria; Janssen: Honoraria. van der Poel: Takeda: Honoraria; Kite, a Gilead company: Honoraria. Jiménez Ubieto: Janssen: Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Speakers Bureau; Regeneron Pharmaceuticals, Inc.: Consultancy; Sandoz: Speakers Bureau; Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Incyte: Speakers Bureau; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Armand: Merck: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Genmab: Consultancy; Enterome: Consultancy; Genentech/Roche: Consultancy, Research Funding; ATB Therapeutics: Consultancy; Foresight: Consultancy; Regeneron: Consultancy; Kite: Research Funding; Adaptive: Research Funding; IGM: Research Funding; AstraZeneca: Research Funding. Domingo Domenech: Ideogen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol Myers Squibb-Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gonzalez Barca: Janssen: Consultancy, Other: Travel funding, Speakers Bureau; AstraZeneca: Speakers Bureau; Roche: Speakers Bureau; Takeda: Speakers Bureau; Novartis: Consultancy; Beigene: Consultancy; Lilly: Consultancy; Incyte: Consultancy, Speakers Bureau; Abbvie: Consultancy, Other: Travel funding, Speakers Bureau; EUSAPharma: Consultancy, Other: Travel funding, Speakers Bureau; Kiowa: Consultancy, Speakers Bureau; Gilead: Consultancy. Sureda Balari: Bluebird: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Consultancy; GSK: Consultancy, Honoraria, Speakers Bureau; EBMT: Other: President; GETH-TC: Other: President; Alexion: Honoraria; Roche: Honoraria, Other: Travel Expenses; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau; Takeda Pharmaceutical: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau. Mussetti: Gilead: Research Funding; SANOFI: Other: speaking and teaching; JAZZ PHARMA: Other: speaking and teaching; Atara, Takeda: Other: Participation in clinical trials (PI); Merck, Jazz Pharma: Other: Honoraria for advisory board activities; Takeda, BMS , Gilead, Sanofi: Other: Honoraria for lectures.